BRPI0923731A2 - "formulações injetáveis de toxinas botulínicas". - Google Patents

"formulações injetáveis de toxinas botulínicas".

Info

Publication number
BRPI0923731A2
BRPI0923731A2 BRPI0923731A BRPI0923731A BRPI0923731A2 BR PI0923731 A2 BRPI0923731 A2 BR PI0923731A2 BR PI0923731 A BRPI0923731 A BR PI0923731A BR PI0923731 A BRPI0923731 A BR PI0923731A BR PI0923731 A2 BRPI0923731 A2 BR PI0923731A2
Authority
BR
Brazil
Prior art keywords
injectable formulations
botulinum toxins
botulinum
toxins
injectable
Prior art date
Application number
BRPI0923731A
Other languages
English (en)
Inventor
Curtis L Ruegg
Hongran F Stone
Jacob M Waugh
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42285690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0923731(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of BRPI0923731A2 publication Critical patent/BRPI0923731A2/pt
Publication of BRPI0923731B1 publication Critical patent/BRPI0923731B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/592—Mixtures of compounds complementing their respective functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
BRPI0923731-3A 2008-12-31 2009-12-28 Composições para uso em um método não-terapêutico de administração de toxina botulínica, seus usos e método de preparação BRPI0923731B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14206308P 2008-12-31 2008-12-31
US61/142,063 2008-12-31
PCT/US2009/069576 WO2010078242A1 (en) 2008-12-31 2009-12-28 Injectable botulinum toxin formulations

Publications (2)

Publication Number Publication Date
BRPI0923731A2 true BRPI0923731A2 (pt) 2016-01-19
BRPI0923731B1 BRPI0923731B1 (pt) 2024-02-06

Family

ID=42285690

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923731-3A BRPI0923731B1 (pt) 2008-12-31 2009-12-28 Composições para uso em um método não-terapêutico de administração de toxina botulínica, seus usos e método de preparação

Country Status (25)

Country Link
US (5) US9956435B2 (pt)
EP (2) EP3332805B1 (pt)
JP (6) JP5866202B2 (pt)
KR (4) KR101753242B1 (pt)
CN (2) CN102300584A (pt)
AU (5) AU2009332947C1 (pt)
BR (1) BRPI0923731B1 (pt)
CA (1) CA2749757C (pt)
CO (1) CO6400199A2 (pt)
CY (1) CY1120137T1 (pt)
DK (2) DK2379104T3 (pt)
ES (2) ES2908616T3 (pt)
HK (1) HK1256878A1 (pt)
HR (1) HRP20180739T1 (pt)
HU (1) HUE037595T2 (pt)
IL (3) IL213668A (pt)
LT (1) LT2379104T (pt)
MX (1) MX2011007059A (pt)
NO (1) NO2379104T3 (pt)
PL (1) PL2379104T3 (pt)
PT (1) PT2379104T (pt)
RU (1) RU2011125775A (pt)
SG (3) SG10201405582YA (pt)
SI (1) SI2379104T1 (pt)
WO (1) WO2010078242A1 (pt)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9211248B2 (en) * 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1734984A4 (en) 2004-03-03 2009-07-29 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL DIAGNOSIS AND THERAPEUTIC TRANSPORT
RU2007136616A (ru) * 2005-03-03 2009-04-10 Риванс Терапьютикс, Инк. (Us) Композиция и способ для местного применения и чрескожного введения ботулинового токсина
US20100093639A1 (en) * 2006-12-29 2010-04-15 Revance Therapeutics, Inc. Transport Molecules Using Reverse Sequence HIV-TAT Polypeptides
PT2178549T (pt) * 2007-07-26 2016-12-20 Revance Therapeutics Inc Péptido antimicrobiano e suas composições
US7967795B1 (en) 2010-01-19 2011-06-28 Lamodel Ltd. Cartridge interface assembly with driving plunger
EP2195052B1 (en) 2007-10-02 2019-09-04 Medimop Medical Projects Ltd. External drug pump
US10420880B2 (en) 2007-10-02 2019-09-24 West Pharma. Services IL, Ltd. Key for securing components of a drug delivery system during assembly and/or transport and methods of using same
US9656019B2 (en) 2007-10-02 2017-05-23 Medimop Medical Projects Ltd. Apparatuses for securing components of a drug delivery system during transport and methods of using same
US9345836B2 (en) 2007-10-02 2016-05-24 Medimop Medical Projects Ltd. Disengagement resistant telescoping assembly and unidirectional method of assembly for such
ES2524312T3 (es) 2008-03-14 2014-12-05 Allergan, Inc. Ensayos de actividad de serotipo A de toxina botulínica de base inmunológica
US9393369B2 (en) 2008-09-15 2016-07-19 Medimop Medical Projects Ltd. Stabilized pen injector
DK2379104T3 (en) * 2008-12-31 2018-04-30 Revance Therapeutics Inc Injectable botulinum toxin formulations
SG177357A1 (en) * 2009-06-25 2012-02-28 Revance Therapeutics Inc Albumin-free botulinum toxin formulations
US10071196B2 (en) 2012-05-15 2018-09-11 West Pharma. Services IL, Ltd. Method for selectively powering a battery-operated drug-delivery device and device therefor
US8157769B2 (en) 2009-09-15 2012-04-17 Medimop Medical Projects Ltd. Cartridge insertion assembly for drug delivery system
US10071198B2 (en) 2012-11-02 2018-09-11 West Pharma. Servicees IL, Ltd. Adhesive structure for medical device
CN102666396B (zh) * 2009-10-21 2015-05-13 雷文斯治疗公司 用于纯化非复合的肉毒杆菌神经毒素的方法和系统
WO2011063395A2 (en) * 2009-11-23 2011-05-26 The Johns Hopkins University Lateral flow device for diagnosing microbial infections
US10585098B2 (en) 2009-11-23 2020-03-10 The Johns Hopkins University Optimizing diagnostics for galactofuranose containing antigens
US8348898B2 (en) 2010-01-19 2013-01-08 Medimop Medical Projects Ltd. Automatic needle for drug pump
US9452261B2 (en) * 2010-05-10 2016-09-27 Medimop Medical Projects Ltd. Low volume accurate injector
KR101134146B1 (ko) * 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
HUE035057T2 (en) * 2011-01-07 2018-05-02 Revance Therapeutics Inc Topical preparation containing Botulinum toxin and colorant
USD702834S1 (en) 2011-03-22 2014-04-15 Medimop Medical Projects Ltd. Cartridge for use in injection device
US9072827B2 (en) 2012-03-26 2015-07-07 Medimop Medical Projects Ltd. Fail safe point protector for needle safety flap
CA2889833A1 (en) * 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US9421323B2 (en) 2013-01-03 2016-08-23 Medimop Medical Projects Ltd. Door and doorstop for portable one use drug delivery apparatus
US9011164B2 (en) 2013-04-30 2015-04-21 Medimop Medical Projects Ltd. Clip contact for easy installation of printed circuit board PCB
RU2535115C1 (ru) 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
WO2015095195A1 (en) 2013-12-16 2015-06-25 The Johns Hopkins University Interferon-gamma release assays for diagnosis of invasive fungal infections
ES2642916T3 (es) * 2014-06-06 2017-11-20 Galit KLEINER-FISMAN Toxina botulínica para su uso en el tratamiento de la paratonia
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
EP3747427A1 (en) * 2014-07-31 2020-12-09 Allergan, Inc. Formulations of biologics for intravesical instillation
EP3188706B1 (en) * 2014-09-02 2019-10-09 American Silver, LLC Botulinum toxin and colloidal silver particles
WO2016102068A1 (en) * 2014-12-23 2016-06-30 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled container
US10293120B2 (en) 2015-04-10 2019-05-21 West Pharma. Services IL, Ltd. Redundant injection device status indication
KR102099326B1 (ko) * 2015-04-13 2020-04-09 주식회사 엘지생활건강 폴리페놀 전달용 용해성 마이크로니들
US10391289B2 (en) 2015-04-13 2019-08-27 Lg Household & Health Care Ltd. Soluble microneedle containing ingredient for controlling release of neurotransmitters
US10149943B2 (en) 2015-05-29 2018-12-11 West Pharma. Services IL, Ltd. Linear rotation stabilizer for a telescoping syringe stopper driverdriving assembly
US11207465B2 (en) 2015-06-04 2021-12-28 West Pharma. Services Il. Ltd. Cartridge insertion for drug delivery device
US9987432B2 (en) 2015-09-22 2018-06-05 West Pharma. Services IL, Ltd. Rotation resistant friction adapter for plunger driver of drug delivery device
US10576207B2 (en) 2015-10-09 2020-03-03 West Pharma. Services IL, Ltd. Angled syringe patch injector
JP7017512B2 (ja) 2015-10-09 2022-02-08 ウェスト ファーマ サービシーズ イスラエル リミテッド 充填済流体容器の屈曲流体路型付属物
JP6955491B2 (ja) 2015-10-29 2021-10-27 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法
JP6885960B2 (ja) 2016-01-21 2021-06-16 ウェスト ファーマ サービシーズ イスラエル リミテッド 視覚的インジケータを有する薬剤デリバリデバイス
EP3711793B1 (en) 2016-01-21 2021-12-01 West Pharma Services IL, Ltd. A method of connecting a cartridge to an automatic injector
WO2017127215A1 (en) 2016-01-21 2017-07-27 Medimop Medical Projects Ltd. Needle insertion and retraction mechanism
US20170209553A1 (en) * 2016-01-22 2017-07-27 Transderm, Inc. Delivery of botulinum with microneedle arrays
WO2017161076A1 (en) 2016-03-16 2017-09-21 Medimop Medical Projects Ltd. Staged telescopic screw assembly having different visual indicators
JP6957525B2 (ja) 2016-06-02 2021-11-02 ウェスト ファーマ サービシーズ イスラエル リミテッド ３つの位置による針の退避
CN109562229B (zh) 2016-08-01 2021-07-13 西医药服务以色列有限公司 抗旋转药筒销
US11730892B2 (en) 2016-08-01 2023-08-22 West Pharma. Services IL, Ltd. Partial door closure prevention spring
TW202247855A (zh) 2016-09-13 2022-12-16 美商愛力根公司 非蛋白梭菌毒素組成物
CA3044219A1 (en) * 2016-11-21 2018-05-24 Eirion Therapeutics, Inc. Transdermal delivery of large agents
RU2022102750A (ru) * 2017-03-22 2022-03-28 Бонти, Инк. Применение ботулинических нейротоксинов в лечении
CN107185042B (zh) * 2017-04-29 2020-09-01 杭州维多利亚医疗美容医院有限公司 一种美容注射剂及其制备方法
CN110996979A (zh) * 2017-05-18 2020-04-10 雷文斯治疗公司 颈肌张力障碍的治疗方法
CN113855913A (zh) 2017-05-30 2021-12-31 西部制药服务有限公司(以色列) 用于穿戴式注射器的模块化驱动机构
EP3675900A4 (en) * 2017-08-28 2021-05-05 Revance Therapeutics, Inc. TRANSMUCOSAL BOTULINUM TOXIN COMPOSITIONS, KITS, AND METHODS FOR TREATMENT OF BLADDER DISORDER
KR20190038292A (ko) * 2017-09-29 2019-04-08 한국프라임제약주식회사 효능 지속시간이 연장된 보툴리눔 독소 조성물
CA3081596A1 (en) * 2017-11-03 2019-05-09 Revance Therapeutics, Inc. Botulinum toxin formulations and methods of use thereof in plantar fasciitis with extended duration of effect
BR112020011098A2 (pt) * 2017-12-04 2020-11-17 Revance Therapeutics, Inc. formulações injetáveis de toxina botulínica e métodos de uso das mesmas que têm alta taxa de resposta e longa duração de efeito
US11857767B2 (en) 2017-12-22 2024-01-02 West Pharma. Services IL, Ltd. Injector usable with different dimension cartridges
KR102088104B1 (ko) 2018-06-29 2020-03-11 호서대학교 산학협력단 개망초 꽃 에센셜 오일을 포함하는 신경 근육 관련 질환 예방 및 치료용 조성물
WO2020117564A1 (en) 2018-12-03 2020-06-11 Eirion Therapeutics, Inc. Improved delivery of large agents
US20220296503A1 (en) 2019-05-14 2022-09-22 Eirion Therapeutics, Inc. Delaying peak effect and/or extending duration of response
CN116041452A (zh) 2020-03-31 2023-05-02 台湾浩鼎生技股份有限公司 A型肉毒杆菌毒素复合物、其配制剂和使用方法
JP2023521123A (ja) * 2020-04-08 2023-05-23 メディトックス インク． 吐出速度調節が容易であり、安定したボツリヌム毒素事前充填の注射器剤形
CN115916236A (zh) 2020-06-12 2023-04-04 凯尔格恩有限公司 包含五肽作为活性成分的组合物
KR20220114183A (ko) * 2021-02-08 2022-08-17 주식회사 대웅 장기 저장이 가능한 보툴리눔 독소 동결건조 제형 조성물
KR20230171400A (ko) * 2022-06-10 2023-12-20 (주)메디톡스 보툴리눔 독소 안정화 조성물, 이를 포함하는 보툴리눔 독소 제제 및 이에 사용하기 위한 폴리펩티드

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
CA2124690C (en) 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
EP1421948B1 (en) 1993-12-28 2008-10-08 Allergan, Inc. Use of botulinum toxins against sweating in humans
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US20030095927A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
CA2319113A1 (en) 1998-01-26 1999-07-29 University Of Massachusetts Biologically active hemagglutinin from type a clostridium botulinum and methods of use
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6358917B1 (en) 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6544548B1 (en) 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6844324B1 (en) 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
IL149778A0 (en) 1999-11-22 2002-11-10 Universal Preservation Technologies Inc Preservation of sensitive biological material
ES2237551T3 (es) 2000-02-08 2005-08-01 Allergan, Inc. Composiciones farmaceuticas que contienen toxina botulinica.
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US6670322B2 (en) 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US20030215412A1 (en) * 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
JP5610659B2 (ja) 2000-07-21 2014-10-22 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 多成分生物学的輸送システム
US6787517B1 (en) 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
WO2003000193A2 (en) 2001-06-21 2003-01-03 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
EP1475101B1 (en) 2002-02-14 2010-10-27 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
AU2003231878A1 (en) 2002-05-31 2003-12-19 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
RU2206337C1 (ru) 2002-10-29 2003-06-20 Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" Лекарственный препарат для лечения мышечных дистоний и способ его получения
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US20060210614A1 (en) * 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
EP1734984A4 (en) 2004-03-03 2009-07-29 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL DIAGNOSIS AND THERAPEUTIC TRANSPORT
PT2985039T (pt) 2004-03-03 2018-11-09 Revance Therapeutics Inc Aplicação tópica e administração transdérmica de toxinas botulínicas
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
KR100852821B1 (ko) 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소를 포함하는 치료 조성물
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
ES2526913T3 (es) 2004-08-04 2015-01-16 Ipsen Biopharm Limited Composición farmacéutica que contiene neurotoxina 2 botulínica
ES2526912T3 (es) 2004-08-04 2015-01-16 Ipsen Biopharm Limited Composición farmacéutica que contiene neurotoxina botulínica A2
GB2419526A (en) 2004-10-28 2006-05-03 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
US7838011B2 (en) 2005-02-14 2010-11-23 Pankaj Modi Stabilized protein compositions for topical administration and methods of making same
DK1853623T3 (da) * 2005-03-03 2013-07-15 Allergan Inc Dyreprodukt-frit system og fremgangsmåde til oprensning af et botulinumtoksin
ATE507236T1 (de) * 2005-03-03 2011-05-15 Revance Therapeutics Inc Zusammensetzungen und methoden zur topischen anwendung und zur transdermalen verabreichung eines oligopeptids
RU2007136616A (ru) 2005-03-03 2009-04-10 Риванс Терапьютикс, Инк. (Us) Композиция и способ для местного применения и чрескожного введения ботулинового токсина
CN101228187A (zh) * 2005-03-25 2008-07-23 特拉维夫大学拉莫特有限公司 针对突变p53的共同表位的人合成单链抗体及其用途
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
EP1948230A4 (en) 2005-11-17 2010-03-10 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL ADMINISTRATION OF BOTULINUM TOXIN CONTAINING LESS NON-TOXIC PROTEINS
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
WO2008082889A2 (en) * 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat
JP2010529000A (ja) 2007-06-01 2010-08-26 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー ボツリヌス毒素の神経毒成分をベースにした温度に安定な筋弛緩薬の提供方法
PT2178549T (pt) 2007-07-26 2016-12-20 Revance Therapeutics Inc Péptido antimicrobiano e suas composições
WO2009056651A1 (en) 2007-11-02 2009-05-07 Cytos Biotechnology Ag Angiotensin-carrier formulation
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
KR20090120222A (ko) 2008-05-19 2009-11-24 (주)메디톡스 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법
WO2010056922A2 (en) * 2008-11-12 2010-05-20 Kythera Biopharmaceuticals, Inc. Systems and methods for delivery of biologically active agents
KR20160103551A (ko) 2008-12-10 2016-09-01 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
DK2379104T3 (en) 2008-12-31 2018-04-30 Revance Therapeutics Inc Injectable botulinum toxin formulations
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
SG177357A1 (en) 2009-06-25 2012-02-28 Revance Therapeutics Inc Albumin-free botulinum toxin formulations
CN102666396B (zh) 2009-10-21 2015-05-13 雷文斯治疗公司 用于纯化非复合的肉毒杆菌神经毒素的方法和系统
JP5932654B2 (ja) 2009-10-30 2016-06-08 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 治療組成物又は美容組成物を局所的に塗布する装置及び方法
WO2012048854A2 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
HUE035057T2 (en) 2011-01-07 2018-05-02 Revance Therapeutics Inc Topical preparation containing Botulinum toxin and colorant
RU2574011C2 (ru) 2011-03-31 2016-01-27 Меди-Токс Инк. Лиофилизированный препарат ботулотоксина
WO2013130535A1 (en) 2012-02-27 2013-09-06 Newgen Biopharma Corporation Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
WO2016102068A1 (en) 2014-12-23 2016-06-30 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled container
EP3679946B1 (en) 2016-05-27 2022-01-05 Ipsen Biopharm Limited Liquid neurotoxin formulation stabilized with tryptophan or tyrosine

Also Published As

Publication number Publication date
JP2019194251A (ja) 2019-11-07
IL281675A (en) 2021-05-31
JP6559849B2 (ja) 2019-08-14
CA2749757A1 (en) 2010-07-08
HRP20180739T1 (hr) 2018-06-29
CA2749757C (en) 2024-03-26
AU2009332947A1 (en) 2011-07-07
US20100168023A1 (en) 2010-07-01
SG10201405582YA (en) 2014-10-30
AU2009332947B2 (en) 2016-07-07
US20200215357A1 (en) 2020-07-09
JP6145465B2 (ja) 2017-06-14
BRPI0923731B1 (pt) 2024-02-06
NO2379104T3 (pt) 2018-07-28
JP2018184460A (ja) 2018-11-22
MX2011007059A (es) 2011-09-15
IL213668A0 (en) 2011-07-31
SI2379104T1 (en) 2018-05-31
JP5866202B2 (ja) 2016-02-17
EP2379104A1 (en) 2011-10-26
CN107343859A (zh) 2017-11-14
AU2016238949A1 (en) 2016-10-27
AU2023229550A1 (en) 2023-11-23
EP2379104A4 (en) 2013-11-27
US20240058628A1 (en) 2024-02-22
KR20190091376A (ko) 2019-08-05
ES2669020T3 (es) 2018-05-23
AU2016238949C1 (en) 2018-11-01
IL254558B (en) 2021-04-29
EP3332805B1 (en) 2022-02-23
ES2908616T3 (es) 2022-05-03
KR20170077292A (ko) 2017-07-05
RU2011125775A (ru) 2013-02-10
US20110268765A1 (en) 2011-11-03
DK3332805T3 (da) 2022-05-16
US20180214717A1 (en) 2018-08-02
AU2018253620A1 (en) 2018-11-22
AU2021200561B2 (en) 2023-06-15
PT2379104T (pt) 2018-03-26
IL254558A0 (en) 2017-11-30
CY1120137T1 (el) 2018-12-12
LT2379104T (lt) 2018-04-10
AU2021200561A1 (en) 2021-02-25
JP2017178954A (ja) 2017-10-05
KR102179926B1 (ko) 2020-11-17
IL213668A (en) 2017-11-30
KR102363878B1 (ko) 2022-02-16
CN102300584A (zh) 2011-12-28
SG172812A1 (en) 2011-08-29
SG10202100698QA (en) 2021-02-25
KR20110117667A (ko) 2011-10-27
DK2379104T3 (en) 2018-04-30
HK1256878A1 (zh) 2019-10-04
AU2009332947C1 (en) 2019-01-03
JP6976997B2 (ja) 2021-12-08
US11471708B2 (en) 2022-10-18
KR101753242B1 (ko) 2017-07-20
PL2379104T3 (pl) 2018-07-31
AU2018253620B2 (en) 2020-10-29
EP2379104B1 (en) 2018-02-28
CO6400199A2 (es) 2012-03-15
JP2012514003A (ja) 2012-06-21
KR20200131348A (ko) 2020-11-23
HUE037595T2 (hu) 2018-09-28
EP3332805A1 (en) 2018-06-13
US9956435B2 (en) 2018-05-01
KR102005930B1 (ko) 2019-07-31
AU2016238949B2 (en) 2018-07-26
WO2010078242A1 (en) 2010-07-08
JP2022028770A (ja) 2022-02-16
JP2015134784A (ja) 2015-07-27

Similar Documents

Publication Publication Date Title
BRPI0923731A2 (pt) "formulações injetáveis de toxinas botulínicas".
LTPA2018014I1 (lt) Farmacinė kompozicija 514
BRPI0913806A2 (pt) "composição"
BRPI0916123A2 (pt) "composição de xampu concentrada"
BRPI0910229A2 (pt) Tetramatos de 4';4'-dioxaspiro espirociclicamente substituídos
BRPI0906607A2 (pt) Agentes de coalescência eficazes.
BRPI0915731A2 (pt) composição de graxa.
BRPI0822830A2 (pt) Seringa com mecanismo de desativação
BRPI0915732A2 (pt) composição de graxa.
FR2929661B1 (fr) Retenue axiale d'aubes de compresseur.
BRPI0820512A2 (pt) "plataforma de plástico aperfeiçoada"
BRPI0907268A2 (pt) "seringa de segurança"
BRPI0923047A2 (pt) "conjugados de proteínas-oligossacarídeos".
BRPI0924425A2 (pt) "combinações de substâncias ativas sinergéticas".
IT1392101B1 (it) Composizione comprendente isoflavoni
BRPI0912928A2 (pt) "composto, e, composição isenta de pirogênio"
BRPI1006024A2 (pt) composição cosmética emulsificada
BRPI0716046A2 (pt) composiÇÕes de nanopartÍcula.
BRPI0916129A2 (pt) "reforço"
BRPI0914063A2 (pt) composição de xampu concentrado
BRPI0716458A2 (pt) Composição de vulcanizado
BRPI0914503A2 (pt) "composição de shampoo concentrado"
FR2937049B1 (fr) Composition de nettoyage.
BRPI0918637A2 (pt) composição antimicrobiana.
BRPI0916363A2 (pt) derivados de 4,5-di-hidro-oxazol-2-ila

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/12/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.